Comparative Pharmacology
Head-to-head clinical analysis: ALKERAN versus BICNU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERAN versus BICNU.
ALKERAN vs BICNU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA synthesis and transcription, leading to apoptosis.
Carmustine (BCNU) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibits DNA synthesis, and carbamoylates proteins.
Melphalan (Alkeran): 0.25 mg/kg/day orally for 4 consecutive days, repeated every 6 weeks; or 16 mg/m^2 IV over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks.
150-200 mg/m2 IV every 6 weeks, administered as a single dose or divided into 2 doses on consecutive days.
None Documented
None Documented
Terminal half-life: 1.5–2.5 hours (may extend to 4–5 hours in renal impairment); clinically relevant for dosing interval and myelotoxicity monitoring.
The terminal elimination half-life of BCNU is 15-30 minutes for the parent drug, but active metabolites persist with a half-life of 5-6 hours. Due to rapid degradation, the overall cytotoxic effect is prolonged.
Renal: 20–50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: negligible.
Renal excretion accounts for approximately 60-70% of the administered dose, with about 10% excreted unchanged. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Alkylating Agent Antineoplastic
Alkylating Agent Antineoplastic